Company profile
Clearside Biomedical, Inc.
Pipeline5 assets
- CLS-AX (axitinib)CLS-AX / VEGF receptors-1, -2 and -3 / Small molecule tyrosine kinase inhibitor / OphthalmologyWet AMDPhase 3 readyFDA end-of-Phase 2 alignment
- XIPERE (triamcinolone acetonide injectable suspension)XIPERE; ARCATUS / Corticosteroid injectable suspension / OphthalmologyUveitic macular edemaApproved/commercialUnited StatesAustraliaSingaporeUveitic macular edemaClinical development/commercialization partnerChinaDiabetic macular edemaClinical development/commercialization partnerAsia Pacific ex-Japan
- Bel-SarViral-like drug conjugate / Ophthalmology/oncologyChoroidal melanomaPartner clinical development program
- ABBV-RGX-314ABBV-RGX-314 / anti-VEGF / AAV gene therapy / OphthalmologyDiabetic retinopathyPartner clinical development programWet AMDPartner clinical development program
- AvoralstatPlasma kallikrein / Small molecule plasma kallikrein inhibitor / OphthalmologyDiabetic macular edemaPartner clinical development program
Latest news0 items
All newsNo recent headlines yet.
New company coverage will appear here as soon as it is picked up.